IQVIA Holdings Inc. $IQV Shares Acquired by Northwestern Mutual Wealth Management Co.

Key Points

• Northwestern Mutual Wealth Management Co. increased its stake in IQVIA Holdings Inc. by 42.9% during the first quarter, bringing its total to approximately $38.38 million.
• During the recent quarter, IQVIA reported earnings of $2.81 per share, exceeding analysts' estimates, and a revenue of $4.02 billion, marking a year-over-year growth of 5.3%.
• Analysts have set a consensus price target of $228.62 for IQVIA, with most giving it a "Moderate Buy" rating and several firms adjusting their targets to above $190.

Northwestern Mutual Wealth Management Co. increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 217,716 shares of the medical research company's stock after purchasing an additional 65,332 shares during the period. Northwestern Mutual Wealth Management Co. owned 0.13% of IQVIA worth $38,383,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Brighton Jones LLC boosted its stake in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. First Trust Advisors LP lifted its position in shares of IQVIA by 15.3% during the fourth quarter. First Trust Advisors LP now owns 59,966 shares of the medical research company's stock valued at $11,784,000 after buying an additional 7,969 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of IQVIA by 27.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,520 shares of the medical research company's stock valued at $496,000 after buying an additional 544 shares during the last quarter. Syon Capital LLC lifted its position in shares of IQVIA by 34.0% during the fourth quarter. Syon Capital LLC now owns 1,138 shares of the medical research company's stock valued at $224,000 after buying an additional 289 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its position in shares of IQVIA by 63.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 38,860 shares of the medical research company's stock valued at $7,636,000 after buying an additional 15,127 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Stock Performance

Shares of IQVIA stock traded down $0.07 during midday trading on Thursday, hitting $188.73. The company had a trading volume of 1,161,570 shares, compared to its average volume of 1,946,132. The stock has a market cap of $32.08 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.06 and a beta of 1.30. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a fifty day simple moving average of $176.32 and a 200 day simple moving average of $167.99. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the firm posted $2.64 EPS. IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on IQV shares. UBS Group increased their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Barclays increased their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Finally, Truist Financial increased their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.